脑栓通胶囊治疗缺血性卒中的更新证据:随机对照试验的系统评价与Meta分析
该系统评价纳入27项随机对照试验共3139例缺血性卒中患者,评估脑栓通胶囊(NSTC)的疗效与安全性。Meta分析显示NSTC可改善急性和非急性期神经功能、提高长期功能结局、降低脑血管事件复发风险并提升急性期生活质量,未观察到不良事件发生率的显著差异,但证据质量为中到极低。
要点
- NSTC可改善缺血性卒中急性期和非急性期神经功能缺损。
- NSTC降低脑血管病复发风险并提高急性期生活质量。
- NSTC与对照组不良事件发生率无显著差异。
核心结论
- NSTC可能是一种对缺血性卒中有效且安全的治疗选择,可改善不同时期神经功能并在二级预防中具有一定临床价值。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库纳入27项随机对照试验,共3139例缺血性卒中患者。
主要发现
- NSTC改善急性期神经功能(MD=-2.53;95%CI:-2.91,-2.15;p<0.00001)。
- NSTC改善非急性期神经功能(MD=-3.70;95%CI:-5.82,-1.58;p=0.0006)。
- NSTC降低长期mRS评分(MD=-0.68;95%CI:-1.09,-0.26;p=0.001)。
- NSTC降低脑血管病复发风险(RR=0.43;95%CI:0.27,0.70;p=0.0006)并提高急性期生活质量(MD=23.88;95%CI:16.63,31.13;p<0.00001)。
- NSTC组与对照组不良事件发生率未见显著差异,证据质量为中到极低。
关键数值与推荐
- 主要结局:急性期NIHSS和非急性期3个月mRS;次要结局包括非急性期NIHSS、mRS、BI、MBI、SS-QOL和脑血管事件复发率。
临床怎么用
- 缺血性卒中患者可考虑使用NSTC以改善神经功能、长期功能结局和生活质量,并可能降低复发风险。
局限性
- 纳入试验质量较差且存在异质性,证据质量为中到极低,需要更大规模标准化随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke is a serious health issue that can result in death or disability, leading to a significant economic strain on society and families. A growing number of studies have shown that the Naoshuantong capsule (NSTC) is beneficial as a treatment for ischemic stroke (IS) in recent years. Our study aims to provide an update on the safety and efficacy of the NSTC in IS patients. METHODS: We thoroughly searched eight databases to identify suitable randomized controlled trials (RCTs) assessing the effectiveness of the NSTC in the treatment of IS. The National Institute of Health Stroke Scale (NIHSS) for an acute period and modified Rankin Scale (mRS) at 3 months for a non-acute period were considered the primary outcome, and secondary outcomes included the NIHSS for a non-acute period, mRS, Barthel Index (BI), modified Barthel Index (MBI), Stroke-specific Quality of life (SS-QOL), and the recurrence rate of cerebrovascular events. Subsequently, its quality was assessed using the Cochrane risk assessment scale. Statistical analysis was conducted using RevMan 5.3 and Stata 14.0. RESULTS: A total of 27 RCTs were included, which involved 3,139 patients. The results showed that the NSTC improved neurological function not only in the acute period (MD = -2.53; 95% CI: -2.91, -2.15; p < 0.00001) but also in the non-acute period (MD = -3.70; 95% CI: -5.82, -1.58; p = 0.0006) and improved the long-term functional outcomes with lower mRS scores (MD = -0.68; 95% CI: -1.09, -0.26; p = 0.001). At the same time, the NSTC decreased the risk of cerebrovascular disease recurrence (RR = 0.43; 95% CI: 0.27, 0.70; p = 0.0006) and increased the quality of life in the acute period (MD = 23.88; 95% CI: 16.63, 31.13; p < 0.00001). Significant disparities in the incidence of adverse events between the NSTC and control groups were not observed. The certainty of evidence was estimated as moderate to very low. CONCLUSION: The NSTC emerges as a potentially efficacious and safe treatment option for IS. NSTC could improve neurological function in different period of IS, and it has certain clinical value in secondary prevention. As a result of the poor quality and heterogeneity of the included trials, larger and standardized RCTs are needed to validate NSTC in IS treatment. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=482981, identifier CRD42023482981.
引用
- Que C, Wei Y, Yin G, et al. Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2024. PMID: 39391695. doi:10.3389/fphar.2024.1434764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。